6-甲氧基-3-吡啶羧胺 | 7150-23-4

• 物质功能分类: 生物化工 - 抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-甲氧基-3-吡啶羧胺
• 英文名称: 6-methyoxy-3-pyridinecarboxamide
• 英文别名: 6-methoxypyridine-3-carboxamide；6-nethoxy-3-pyridinecarboxamide；6-methoxynicotinamide；JBSNF-000088；JBSF-88
• CAS: 7150-23-4
• 化学式: C₇H₈N₂O₂
• mdl: MFCD00229166
• 分子量: 152.153
• InChiKey: KXDSMFBEVSJYRF-UHFFFAOYSA-N

物化性质

• 熔点：
  178-180°C
• 沸点：
  301.6±22.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Methoxynicotinamide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Methoxynicotinamide
CAS number: 7150-23-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8N2O2
Molecular weight: 152.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

JBSNF-000088（6-甲氧烟酰胺）是一种烟酰胺（NA）的类似物，是Nicotinamide N-methyltransferase (NNMT)的有效抑制剂。其对human NNMT(hNNMT)、monkey NNMT(mkNNMT) 和 mouse NNMT(mNNMT)的IC50值分别为1.8 μM、2.8 μM 和 5.0 μM。

靶点

Target	Value
hNNMT (Cell-free assay)	1.8 μM
mkNNMT (Cell-free assay)	2.8 μM
mNNMT (Cell-free assay)	5.0 μM

体外研究

JBSNF-000088（6-甲氧烟酰胺）对U2OS或分化后的3T3L1细胞的IC50值分别为1.6和6.3 μM。

体内研究

• JBSNF-000088 (6-甲氧烟酰胺) (50 mg/kg；口服给药4周) 显示出显著降低体重百分比，并在第21天表现出显著降低空腹血糖。
• JBSNF-000088 (50 mg/kg；经口灌胃给药，每日两次，共4周) 在第28天显示出显著改善口服葡萄糖耐量，血糖耐受性恢复正常。
• JBSNF-000088 (1 mg/kg；静脉注射给药，持续4小时) 血浆清除率为21 mL/min·kg，稳态分布体积为0.7 L/kg，静脉注射后半衰期仅为0.5小时。
• JBSNF-000088 (10 mg/kg；经口灌胃给药，持续4小时) 最大血药浓度（Cmax）为3568 ng/mL，达峰时间（Tmax）为0.5小时，表明在肠道中的快速吸收，口服后的半衰期为0.4小时。口服生物利用度约为40%。

实验动物模型

• 动物模型：高脂饮食诱导肥胖的小鼠

  • 剂量：50 mg/kg
  • 给药方式：持续4周的经口给药；每日两次，共4周
  • 结果：表现出显著降低体重百分比，并在第21天显示出显著降低空腹血糖。通过经口灌胃给药后，在第28天显现出显著改善口服葡萄糖耐量。

• 动物模型：C57BL/6小鼠

  • 剂量：静脉注射剂量为1 mg/kg，经口灌胃剂量为10 mg/kg（药代动力学研究）
  • 给药方式：静脉注射和经口灌胃；持续4小时
  • 结果：静脉注射后血浆清除率为21 mL/min·kg，稳态分布体积为0.7 L/kg，半衰期仅为0.5小时。口服给药后的最大浓度（Cmax）为3568 ng/mL，达峰时间为0.5小时，表明在肠道中的快速吸收，并且口服后半衰期为0.4小时。

反应信息

• 作为反应物：
  描述：

  6-甲氧基-3-吡啶羧胺 在 sodium hydroxide 、 溴 作用下， 以 四氢呋喃 为溶剂， 生成 5-氨基-2-甲氧基吡啶
  参考文献：
  名称：

  新型氰基胍ATP敏感性钾通道开放剂的结构活性研究，用于膀胱过度活动症的治疗。

  摘要：

  设计并合成了一系列新型氰基胍衍生物。N-（1-苯并三唑-1-基-2,2-二氯丙基）-取代的苯甲酰胺与N-（取代吡啶-3-基）-N'-氰基胍的缩合提供N- {2,2-二氯-1 -[N'-（取代的吡啶-3-基）-N”-氰基胍基]丙基}-取代的苯甲酰胺衍生物。通过FLIPR膜电位染料（KATP-FMP）评估，这些药物是格列本脲可逆的钾通道开放剂和超极化的人膀胱细胞。这些化合物在松弛的电刺激猪膀胱条（膀胱过度活动症的体外模型）中也是有效的全激动剂。在膀胱不稳的猪模型中，评价了活性最高的化合物9的体内功效和选择性。犬的初步药代动力学研究表明，其口服生物利用度极佳，t1 / 2为15小时。讨论了这些试剂的合成，SAR研究和生物学特性。

  DOI：

  10.1021/jm7010194
• 作为产物：
  描述：

  6-甲氧基烟酸甲酯 在 氨 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以82%的产率得到6-甲氧基-3-吡啶羧胺
  参考文献：
  名称：

  Novel nicotinamide analog as inhibitor of nicotinamide N-methyltransferase

  摘要：

  Nicotinamide N-methyltransferase (NNMT) has been linked to obesity and diabetes. We have identified a novel nicotinamide (NA) analog, compound 12 that inhibited NNMT enzymatic activity and reduced the formation of 1-methyl-nicotinamide (MNA), the primary metabolite of NA by ∼80% at 2 h when dosed in mice orally at 50 mg/kg.

  DOI：

  10.1016/j.bmcl.2018.01.058

文献信息

• [EN] BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS<br/>[FR] DÉRIVÉS BIARYLE EN TANT QU'INHIBITEURS D'INTERACTION PROTÉINE-PROTÉINE YAP/TAZ-TEAD
  申请人：NOVARTIS AG

  公开号：WO2021186324A1

  公开（公告）日：2021-09-23

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

  本发明提供了化合物(I)或其药学上可接受的盐；(I)制造所述化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合物和包括所述化合物的药物组合。
• [EN] INDAZOLOPYRIMIDINONES AS FIBRINOLYSIS INHIBITORS<br/>[FR] INDAZOLOPYRIMIDINONES COMME INHIBITEURS DE LA FIBRINOLYSE
  申请人：BAYER PHARMA AG

  公开号：WO2016173948A1

  公开（公告）日：2016-11-03

  The present application relates to novel substituted indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代吲唑吡咯嘧啶酮，其制备方法，以及用于治疗和/或预防疾病的化合物，特别是用于治疗和/或预防患有或不患有基础遗传或获得性止血障碍的患者急性和复发性出血的方法，其中出血与从重经期出血、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤等一组疾病或医疗干预有关。
• [EN] ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS<br/>[FR] INHIBITEURS DE RÉCEPTEURS NICOTINIQUES ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：WYETH CORP

  公开号：WO2010009290A1

  公开（公告）日：2010-01-21

  The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.

  本发明提供了化合物和组合物，制备它们的方法，以及利用它们调节α7烟碱乙酰胆碱受体和/或治疗各种疾病、疾病和症状的方法。所提供的化合物可以影响神经系统、精神病学和/或炎症系统等方面。
• Pyrazole compounds and their use as antidiabetes agents
  申请人：Takagi Masaki

  公开号：US20070032529A1

  公开（公告）日：2007-02-08

  The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R 1 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group, R 3 represents a halogen atom, a hydroxyl group, a C 1-6 alkyl group, a halo C 1-6 alkyl group, a C 1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C 1-6 alkylsulfonylamino group, R 4 and R 5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, a C 3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C 7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.

  本发明提供了一种具有肝糖原磷酸化酶抑制活性的吡唑化合物，用作糖尿病的治疗或预防剂，所述吡唑化合物由以下通用式（I）表示：其中环Q代表芳基或杂芳基，R1代表氢原子、卤原子、C1-6烷基或C1-6烷氧基，R2代表卤原子、C1-6烷基、C1-6烷氧基或偶氮基，R3代表卤原子、羟基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、偶氮基、氨基、酰胺基或C1-6烷基磺酰胺基，R4和R5彼此相同或不同，代表氢原子、取代或未取代的C1-6烷基、取代或未取代的C3-8环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14芳基烷基、杂芳基等，或其药理学上可接受的盐。
• [EN] DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE DIHYDRO-CYCLOPENTA-ISOQUINOLINE
  申请人：UCB BIOPHARMA SRL

  公开号：WO2021130255A1

  公开（公告）日：2021-07-01

  The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

  本发明涉及式（I）的二氢环戊基异喹啉衍生物，其制备方法，含有它们的药物组合物以及它们在治疗由IgE引起的疾病（如过敏反应、非过敏肥大细胞反应或某些自身免疫反应）中的用途，特别是由IgE与FcεRI受体相互作用引起的疾病。